Cara’s Phase III Success In CKD-Pruritus Puts NDA Filing In Sight

Second Phase III study expected later this year, but Cara wants to discuss the possibility of accelerated filing with the US FDA. It also has an oral formulation in Phase II for less severe CKD patients.